JP2008528511A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528511A5
JP2008528511A5 JP2007552348A JP2007552348A JP2008528511A5 JP 2008528511 A5 JP2008528511 A5 JP 2008528511A5 JP 2007552348 A JP2007552348 A JP 2007552348A JP 2007552348 A JP2007552348 A JP 2007552348A JP 2008528511 A5 JP2008528511 A5 JP 2008528511A5
Authority
JP
Japan
Prior art keywords
composition
therapeutic agent
family
heart
sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007552348A
Other languages
English (en)
Other versions
JP5058822B2 (ja
JP2008528511A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/002313 external-priority patent/WO2006081190A2/en
Publication of JP2008528511A publication Critical patent/JP2008528511A/ja
Publication of JP2008528511A5 publication Critical patent/JP2008528511A5/ja
Application granted granted Critical
Publication of JP5058822B2 publication Critical patent/JP5058822B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (17)

  1. 第1の治療薬を単独でか、または第2の治療薬と組み合わせて含む、虚血、虚血性心臓外傷、うっ血性心不全、心筋梗塞、冠状動脈疾患および/または心筋症の処置のための組成物であって、該第1の治療薬は、少なくとも第1の単離されたポリペプチド、またはそのスプライスバリアントもしくは活性なフラグメントを含み、
    該組成物は、ヒト被験体の心臓への全身送達または局所送達のためのものであり、該治療薬は、FGFファミリーのメンバーまたはEGFファミリーのメンバーであり、該FGFファミリーのメンバーは、FGF5、FGF9、FGF16、またはFGF17であり、EGFファミリーのメンバーは、アンフィレグリン、Epigen、エピレグリン、HB−EGF、またはベータセルリンである、組成物。
  2. 前記組成物が、さらに第2の治療薬を含む、請求項1に記載の組成物。
  3. 前記第2の治療薬が、PDGFファミリーのメンバー、IGFファミリーのメンバーおよびサイモシンβ4のうちの1つ以上を含む、請求項2に記載の組成物。
  4. 前記第2の治療薬が、VEGFファミリーのメンバー、またはその活性なフラグメントである、請求項2に記載の組成物。
  5. 前記組成物が、さらに少なくとも第3の治療薬を含む、請求項2に記載の組成物。
  6. 前記第3の治療薬が、FGFファミリーのメンバーを含み、前記第3の治療薬が、EGFファミリーのメンバーである、請求項に記載の組成物。
  7. 前記治療薬の少なくとも1つが、融合分子である、請求項1に記載の組成物。
  8. 前記融合分子が、融合パートナーを含む、請求項に記載の組成物。
  9. 前記融合パートナーが、ポリマー、免疫グロブリン分子、スクシニル基、フェチュインA、フェチュインB、アルブミン、ロイシンジッパードメイン、オリゴマー形成ドメイン、マンノース結合タンパク質、マクロファージスカベンジャータンパク質、Fc領域またはこれらのいずれかの活性なフラグメントを含む、請求項に記載の組成物。
  10. 生分解性の担体を含む薬学的に許容可能な担体をさらに含む、請求項1に記載の組成物。
  11. 前記生分解性の担体が、多糖を含む、請求項10に記載の組成物。
  12. 前記多糖が、ヒアルロン酸、デキストラン、デキストラン硫酸、コンドロイチン硫酸、デルマタン硫酸、ケラタン硫酸、ヘパリン、ヘパラン硫酸および/またはアルギネートを含む、請求項11に記載の組成物。
  13. 前記組成物が、生物学的マーカーを含む、請求項1に記載の組成物。
  14. 前記組成物が、ゲル組成物である、請求項1に記載の組成物。
  15. 被験体における虚血、虚血性心臓外傷、うっ血性心不全、心筋梗塞、冠状動脈疾患および/または心筋症の処置のためのキットであって、請求項1、2または5のいずれか1項に記載の組成物、該組成物を心臓に送達するためのデバイス、および該組成物を心臓に注入するための指示書を含む、キット。
  16. 前記第1の治療薬が、約1ng〜約10mgの範囲の用量を含む、請求項に記載の組成物
  17. 前記第1の治療薬が、約1ng〜約50mgの量で前記組成物中に存在する、請求項に記載の組成物
JP2007552348A 2005-01-25 2006-01-25 心臓の状態を処置するための組成物および方法 Expired - Fee Related JP5058822B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US64652005P 2005-01-25 2005-01-25
US60/646,520 2005-01-25
US67508605P 2005-04-27 2005-04-27
US60/675,086 2005-04-27
US67585905P 2005-04-29 2005-04-29
US60/675,859 2005-04-29
US70147405P 2005-07-22 2005-07-22
US60/701,474 2005-07-22
US71649105P 2005-09-14 2005-09-14
US60/716,491 2005-09-14
US73981505P 2005-11-25 2005-11-25
US60/739,815 2005-11-25
PCT/US2006/002313 WO2006081190A2 (en) 2005-01-25 2006-01-25 Compositions and methods for treating cardiac conditions

Publications (3)

Publication Number Publication Date
JP2008528511A JP2008528511A (ja) 2008-07-31
JP2008528511A5 true JP2008528511A5 (ja) 2009-03-05
JP5058822B2 JP5058822B2 (ja) 2012-10-24

Family

ID=36740983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007552348A Expired - Fee Related JP5058822B2 (ja) 2005-01-25 2006-01-25 心臓の状態を処置するための組成物および方法

Country Status (9)

Country Link
US (1) US8168588B2 (ja)
EP (2) EP2236153A3 (ja)
JP (1) JP5058822B2 (ja)
AT (1) ATE481978T1 (ja)
AU (1) AU2006208241B2 (ja)
CA (1) CA2590338A1 (ja)
DE (1) DE602006017071D1 (ja)
HK (1) HK1118210A1 (ja)
WO (1) WO2006081190A2 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
EP2269461B1 (en) 2004-07-30 2017-03-22 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
US20100255518A1 (en) 2006-04-04 2010-10-07 Goix Philippe J Highly sensitive system and methods for analysis of troponin
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
EP2098244A1 (en) * 2008-03-04 2009-09-09 Medizinische Hochschule Hannover Pharmaceutical composition for the treatment of myocardial infarction
US8623820B2 (en) 2008-05-02 2014-01-07 University Of Western Ontario FGF-9 and its use relating to blood vessels
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
CN102231987A (zh) * 2008-11-28 2011-11-02 上海泽生科技开发有限公司 纽兰格林和心脏干细胞
WO2010083466A1 (en) * 2009-01-16 2010-07-22 Cedars-Sinai Medical Center Methods and compositions for cardiac tissue regeneration
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
EP2498796B1 (en) 2009-11-09 2017-12-27 AAL Scientifics, Inc. Treatment of heart disease
US9051358B2 (en) * 2009-11-19 2015-06-09 Zhejiang University Nonnatural collagen-like protein and use thereof
MX2012005976A (es) * 2009-12-02 2012-06-25 Cardio3 Biosciences Sa Composiciones farmaceuticas para la estimulacion de los citoblastos.
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
WO2012045096A2 (en) * 2010-10-01 2012-04-05 The Trustees Of Columbia University In The City Of New York Compositions and methods of forming cardiac progenitor cells
JP2013031151A (ja) * 2011-06-20 2013-02-07 Renesas Electronics Corp 暗号通信システムおよび暗号通信方法
CA2869163A1 (en) * 2012-03-30 2013-10-03 University Of Central Florida Research Foundation, Inc. Methods and compositions using fgf-8 to enhance cardiac regeneration and attenuate adverse cardiac remodeling
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
CN110946993A (zh) * 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
EP3200808A4 (en) 2014-10-03 2018-05-16 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
KR101778202B1 (ko) * 2015-06-04 2017-09-13 (주)피앤피바이오팜 안정성이 증가된 인간 섬유아세포 성장인자-2 변이체 및 이의 용도
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CA3023530C (en) * 2016-05-24 2021-02-23 Arris Enterprises Llc Efficient encrypted software distribution mechanism
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
WO2018057542A1 (en) 2016-09-20 2018-03-29 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
US11759482B2 (en) 2017-04-19 2023-09-19 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US20200155648A1 (en) * 2017-06-28 2020-05-21 Children's Medical Center Corporation Promoting lung growth
EP3727351A4 (en) 2017-12-20 2021-10-06 Cedars-Sinai Medical Center MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY
US20230398187A1 (en) * 2019-12-24 2023-12-14 Juvena Therapeutics, Inc. Regenerative Polypeptides and Uses Thereof
CH717226B1 (it) * 2020-07-14 2021-09-30 Contrad Swiss Sa Idrogel per applicazione topica efficace nel limitare la degenerazione di tendini e muscoli.
US11524998B2 (en) 2020-07-16 2022-12-13 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5155214A (en) 1984-03-05 1992-10-13 The Salk Institute For Biological Studies Basic fibroblast growth factor
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5049132A (en) 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
US5269326A (en) 1991-10-24 1993-12-14 Georgetown University Method for transvenously accessing the pericardial space via the right auricle for medical procedures
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20040132190A1 (en) 1995-02-28 2004-07-08 The Regents Of The University Of California Gene therapy for myocardial ischemia
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US5797870A (en) 1995-06-07 1998-08-25 Indiana University Foundation Pericardial delivery of therapeutic and diagnostic agents
DE69735622T2 (de) * 1996-08-16 2007-04-12 MCW Research Foundation, Inc., Milwaukee Knochen morphogenetisches protein und fibroblasten wachstumsfaktor enthaltende zusammensetzungen und methoden zur induzierung der kardiogenese
US6518236B1 (en) * 1996-10-16 2003-02-11 Zymogenetics, Inc. FGF homologs
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
US20040215168A1 (en) 1997-04-30 2004-10-28 Beth Israel Deaconess Medical Center Kit for transvenously accessing the pericardial space via the right atrium
JP4247846B2 (ja) 1997-07-03 2009-04-02 デュピュイ・スパイン・インコーポレーテッド 架橋ポリサッカリド薬物キャリア
US6304769B1 (en) 1997-10-16 2001-10-16 The Regents Of The University Of California Magnetically directable remote guidance systems, and methods of use thereof
GB2332373A (en) * 1997-12-19 1999-06-23 Merck & Co Inc Treatment of coronary and/or peripheral ischemia using an antithrombotic agent and an angiogenesis promoter
US6274712B1 (en) 1997-12-23 2001-08-14 3-Dimensional Pharmaceuticals, Inc. Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
CN100350979C (zh) 1998-02-11 2007-11-28 加利福尼亚大学董事会 核酸和血管活性剂相组合用于加强的基因投递
EP1064356A2 (en) * 1998-03-23 2001-01-03 ZymoGenetics, Inc. Cardiac-derived stem cells
WO2000021548A2 (en) * 1998-10-13 2000-04-20 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6333347B1 (en) 1999-01-29 2001-12-25 Angiotech Pharmaceuticals & Advanced Research Tech Intrapericardial delivery of anti-microtubule agents
JP3106191B1 (ja) * 1999-03-30 2000-11-06 工業技術院長 Fgf−5の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物
JP5704780B2 (ja) 1999-08-13 2015-04-22 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド 脈管形成因子の用量および心筋血流を改善するための投与方法
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US6815418B2 (en) 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US7214369B2 (en) * 2003-05-05 2007-05-08 Mirus Bio Corporation Devices and processes for distribution of genetic material to mammalian limb
US20040023863A1 (en) 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
KR101015682B1 (ko) * 2002-10-08 2011-02-22 아레스 트레이딩 에스.에이. Il-18bp에 결합할 수 있고 제 2 사이토킨의 활성을저해할 수 있는 사이토킨의 용도
CN100379730C (zh) * 2002-12-02 2008-04-09 埃科特莱茵药品有限公司 嘧啶-磺酰胺及其作为内皮素受体拮抗剂的应用
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids

Similar Documents

Publication Publication Date Title
JP2008528511A5 (ja)
Subbiah et al. Materials science and design principles of growth factor delivery systems in tissue engineering and regenerative medicine
Song et al. Regeneration of chronic myocardial infarction by injectable hydrogels containing stem cell homing factor SDF-1 and angiogenic peptide Ac-SDKP
Whelan et al. Fibrin as a delivery system in wound healing tissue engineering applications
Chu et al. Therapeutic angiogenesis: controlled delivery of angiogenic factors
Hajimiri et al. Growth factor conjugation: strategies and applications
Sakiyama-Elbert Incorporation of heparin into biomaterials
Hunt et al. Hydrogels for tissue engineering and regenerative medicine
Chu et al. The effect of a heparin-based coacervate of fibroblast growth factor-2 on scarring in the infarcted myocardium
US20060025343A1 (en) Angiogenically effective unit dose fo FGF and method of adminstering
Worthington et al. β-Hairpin peptide hydrogels for package delivery
Kang et al. Poly (ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system
Layman et al. Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model
Van Hove et al. Depot-based delivery systems for pro-angiogenic peptides: a review
Schesny et al. Preserved bioactivity and tunable release of a SDF1-GPVI bi-specific protein using photo-crosslinked PEGda hydrogels
RU2011101464A (ru) Гликозилированный пептид glp-1
JP2007526330A5 (ja)
WO2008047241A3 (en) Modified corticotropin releasing factor peptides and uses thereof
JP2010505444A5 (ja)
JP2014526441A5 (ja)
US20200222548A1 (en) Synthetic bioconjugates
JP2003519097A (ja) 脈管形成因子の用量および心筋血流を改善するための投与方法
WO2001041812A3 (en) Amphiphilic polymers and polypeptide conjugates comprising same
JP2018523703A5 (ja)
JP2010538020A5 (ja)